Wayne Kuzner | Authors


Continuous Low-Dose Ribociclib Active in Advanced Breast Cancer Causes Less Neutropenia

December 13, 2016

Continuous low-dose ribociclib shows preliminary activity, and has an acceptable safety profile as an alternative to intermittent ribociclib dosing when combined with fulvestrant in the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.